ESALF:OTC-Eisai Co., Ltd (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 101.00

Change

0.00 (0.00)%

Market Cap

USD 29.49B

Volume

100.00

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. Eisai Co., Ltd. has a research collaboration agreement with Wren Therapeutics Ltd. for the discovery of small molecules that target synuclein for the potential treatment of synucleinopathies, including Parkinson's disease and dementia with Lewy bodies; and a collaboration with BioLabs for the launch of the Eisai Innovation Center BioLabs, a shared lab and office space for start-ups to innovate in the field of neurological diseases. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-20 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKGAF MERCK Kommanditgesellschaft au..

N/A

USD80.36B 29.16 17.26
MKKGY MERCK Kommanditgesellschaft au..

N/A

USD79.39B 28.51 17.26
TKPHF Takeda Pharmaceutical Company ..

N/A

USD54.07B 15.78 0.07
ESALY Eisai Co., Ltd

N/A

USD31.03B 81.65 0.19
SFOSF Shanghai Fosun Pharmaceutical ..

N/A

USD23.06B 29.29 4.17
SGIOY Shionogi & Co., Ltd

N/A

USD15.39B 15.49 0.07
SGIOF Shionogi & Co., Ltd

N/A

USD15.14B 15.25 0.07
TEVJF Teva Pharmaceutical Industries..

N/A

USD11.26B 900.00 16.02
BAYP Bayport International Holdings..

N/A

USD10.85B N/A N/A
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21

ETFs Containing ESALF

Symbol Name Weight Mer Price(Change) Market Cap
BIGT:LSE Legal & General UCITS ETF.. 0.00 % 0.49 %

N/A

USD0.03B
XCS5:LSE Xtrackers MSCI India Swap.. 0.00 % 0.75 %

N/A

USD0.08B
XCX5:LSE Xtrackers - MSCI India Sw.. 0.00 % 0.00 %

N/A

USD0.08B
XSD2:LSE Xtrackers ShortDAX x2 Dai.. 0.00 % 0.60 %

N/A

USD0.13B
1621:TSE NEXT FUNDS TOPIX-17 Pharm.. 0.00 % 0.00 %

N/A

USD1.16B
1638:TSE Daiwa ETF TOPIX-17 Pharma.. 0.00 % 0.00 %

N/A

USD0.49B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 44.29% 60% D- 68% D+
Dividend Return 1.07% 63% D 24% F
Total Return 45.35% 60% D- 68% D+
Trailing 12 Months  
Capital Gain 26.36% 47% F 40% F
Dividend Return 1.88% 65% D 24% F
Total Return 28.24% 48% F 40% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 10.49% 47% F 49% F
Dividend Return 31.38% 76% C 95% A
Total Return 41.88% 62% D- 69% D+
Risk Return Profile  
Volatility (Standard Deviation) 66.61% 61% D- 41% F
Risk Adjusted Return 62.87% 96% A 87% B+
Market Capitalization 29.49B 99% A+ 95% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 76.17 13% F 10% F
Price/Book Ratio 4.74 33% F 27% F
Price / Cash Flow Ratio 0.40 23% F 43% F
EV/EBITDA 0.19 81% B- 77% C+
Management Effectiveness  
Return on Equity 5.94% 77% C+ 57% F
Return on Invested Capital -2.62% 59% F 38% F
Return on Assets 3.27% 81% B- 75% C
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.50 67% D+ 67% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.